Autonomic Pharmacology (2024)

Continuing Education Activity

The basis of autonomic pharmacology reflects the physiology of the sympathetic nervous system (SNS) and the parasympathetic nervous system (PSNS) to regulate involuntary reactions to stresses on multiorgan systems within the body. When a pathologic process is present that affects the homeostasis achieved between the SNS and PSNS in this process, either of these branches can become overactive while the other is excessively inhibited. This activity outlines the indications, mechanism of action, safe administration, adverse effects, contraindications, toxicology, and monitoring of the broad array of physiological possibilities when using autonomic pharmacology.

Objectives:

• Identify the four major classes of pharmacological agents in autonomic pharmacology.

• Summarize the mechanism of action of each of the four main categories of autonomic pharmacological agents.

• Review the side effects of each of the four classes of autonomic pharmacological agents.

• Outline interprofessional team strategies for improving care coordination and communication to advance appropriate clinical outcomes with these classes of medications, leading to optimal patient outcomes.

Access free multiple choice questions on this topic.

Indications

The basis of autonomic pharmacology reflects the physiology of the sympathetic nervous system (SNS) and the parasympathetic nervous system (PSNS) to regulate involuntary reactions to stresses on multiorgan systems within the body. When a pathologic process is present that affects the homeostasis achieved between the SNS and PSNS in this process, either of these branches can become overactive while the other is excessively inhibited.[1] This break in homeostasis results in various clinical manifestations that can range in severity from simply presenting rhinorrhea symptomology to fatal presentations like cardiovascular collapse.[2] For a wide range of presentations and severity of pathologies, the agents classified in autonomic pharmacology are indicated to re-establish the homeostasis that the human body attempts to produce via the autonomic nervous system (ANS).[3]

Within autonomic pharmacology, there are four specific categories of drugs based on how they affect the ANS:

1. Cholinomimetics/cholinesterase antagonists

2. Anticholinergics

3. Adrenoreceptor agonists/sympathomimetics

4. Adrenoreceptor antagonists

The clinical indications of medications from each of the four categories are listed below. Important to note is that this isnot a complete list due to the vastness of this topic; the drugs included are representative of each category.

FDA-labeled indications:

Cholinomimetics/Cholinesterase antagonists[4][5][6][7]:

• Bethanechol - postoperative and neurogenic ileus and urinary retention

• Pilocarpine - glaucoma and alleviating the symptoms of Sjogren’s syndrome

• Nicotine - found in smoking cessation regimens

• Cholinesterase inhibitors (neostigmine, edrophonium, pyridostigmine, physostigmine) - the diagnosis and treatment of myasthenia gravis, maintenance treatment of Alzheimer disease, and specifically neostigmine used commonly with glycopyrrolate to reverse neuromuscular blockade in postoperative anesthesia practice

Anticholinergics[8][9][10][11][12][13][14]:

• Atropine - used in ACLS guidelines to correct bradyarrhythmias and in ophthalmic surgery as a retinal dilator

• Ipratropium and tiotropium - correct acute exacerbations of bronchospasm (asthma, COPD), as well as exacerbation prophylaxis for those conditions

• Scopolamine - prevents motion sickness and postoperative nausea/vomiting

• Oxybutynin - urge incontinence and postoperative bladder spasm

• Dicyclomine, glycopyrrolate - can be used for reducing diarrhea output in irritable bowel syndrome;glycopyrrolate can also be added to cholinesterase reversal of neuromuscular blockades in postoperative anesthesia care to prevent bronchospasmand is currently undergoing investigation as an adjunct treatment in COPD

Adrenoreceptor agonists/Sympathomimetics[15][16][17][18][19][20][21]:

• Clonidine - used as an antihypertensive

• Dobutamine, phenylephrine, epinephrine - used to correct severe hypotension in cardiogenic shock and acute heart failure exacerbation;epinephrine specifically also used in ACLS guidelines for non-shockable heart rhythms in cardiac arrest and rapid reversal of fatal anaphylactic reactions

• Albuterol - fast-acting bronchodilator used in acute asthma exacerbations

• Fenoldopam - corrects hypertension

• Bromocriptine - involved in the maintenance of Parkinson disease and conditions involving prolactinoma

Adrenoreceptor antagonists[22][23][24]:

• Phenoxybenzamine, phentolamine - used to correct high catecholamine states

  See Also

  University Of Wyoming, Sublette County 4-H Afterschool in Pinedale, Wyoming (WY)Antiemetic Histamine H1 Receptor Blockers

• Prazosin, doxazosin, terazosin, tamsulosin - indicated to correct urinary retention in benign prostatic hyperplasia

• Beta-blockers (propranolol, metoprolol, labetalol, etc.) - indicated for many cardiovascular conditions since they are in the classification of class II antiarrhythmics; these agents are used to manage tachyarrhythmias, hypertension, angina, heart failure, and migraine prophylaxis

Mechanism of Action

As with the homeostasis established via processes performed by the SNS and PSNS, drugs from each of the four categories listed above also work inversely to each other. The primary mechanism of action for most of these agents are to serve as either agonists or antagonists of specific receptors within these systems.[2] The receptors with their locations and physiologic actions are listed below.

For adrenoreceptors stimulated by norepinephrine (synapses) and epinephrine (endocrine), involved in SNS processes[25][26]:

• Alpha-1 (A1) – located mostly in postsynaptic effector cells found in smooth muscle; effects mediated by IP3/DAG path, include mydriasis due to contraction of radial muscles, constriction of arteries and veins, urinary retention due to internal/external urethral sphincter contraction, and a decrease in renin release from renal juxtaglomerular cells

• Alpha-2 (A2) – located in presynaptic adrenergic terminals found in lipocytes and smooth muscle; effects mediated by decreasing cAMP, including a decrease in norepinephrine release, stimulates platelet aggregation and decreases insulin secretion

• Beta-1 (B1) – located in postsynaptic effector cells in the SA node of the heart, lipocytes, brain, juxtaglomerular apparatus of renal tubules, and the ciliary body epithelium; effects mediated by increasing cAMP, including increased heart rate and the conduction velocity through the cardiac nodes, also increases renin release from renal juxtaglomerular cells

• Beta-2 (B2) – located in postsynaptic effector cells in smooth muscle and cardiac myocytes; effects mediated by increasing cAMP, include vasodilation, bronchiole dilation, increased insulin secretion, and uterine relaxation

• Beta-3 (B3) – located in postsynaptic effector cells in lipocytes and myocardium; similar effects to beta-1 receptors mediated by increasing cAMP

For cholinoreceptors stimulated by acetylcholine, most involved in PSNS processes[27]:

• Muscarinic-1 (M1) – important to note is the only cholinoreceptor involved in an SNS process, located in sweat glands of the skin; effects mediated by IP3/DAG path, include glandular contraction and increased secretion

• Muscarinic-2 (M2) – located in SA and AV nodes and myocardium; effects mediated by decreasing cAMP, include decreasing heart rate and myocardial conduction velocity

• Muscarinic-3 (M3) – located in the smooth muscle of various organ systems; effects mediated by IP3/DAG path, include contraction of theciliary muscle causing miosis, contraction of bronchioles, increased bronchiole secretions, increased GI motility, detrusor muscle contraction, and internal/external urethral sphincter relaxation

• Muscarinic-4 (M4) and Muscarinic (M5) - located primarily in the CNS, e.g., forebrain and substania nigra, respectively

• Nicotinic-N (NN) – located in postsynaptic dendrites of both sympathetic and parasympathetic postganglionic neurons; effects mediated by Na+/K+ depolarization, include increased neurotransmission

• Nicotinic-M (NM) – located in neuromuscular endplates of skeletal muscle; effects mediated by Na+/K+ depolarization, include skeletal muscle contraction

For dopamine receptors, most involved in both SNS and PSNS processes[28]:

• Dopamine 1-5 (D1-5) – located in the CNS, except for Dopamine-1 receptors, which also appear in renal vasculature; effects mediated by cAMP path, include renal artery vasodilation, increased renal blood flow, and modulation of neuroendocrine signaling

In terms of the four categories mentioned, each is an agonist and/or antagonist of the receptors listed. Cholinomimetics have agonist activity at muscarinic receptors augmenting PSNS activity to achieve the desired effects of increasing GI motility and decreasing intraocular pressure.[4][5] Whereas the other agents mentioned work directly on receptors as agonists/antagonists, the subcategory of drugs that also achieve similar effects to cholinomimetics is the cholinesterase antagonists. These agents inhibit acetylcholinesterase enzymes within the synaptic cleft to increase the concentration of acetylcholine, resulting in increased PSNS neurotransmission and facilitating skeletal muscle contraction.[7] Inversely, the anticholinergic agents work to inhibit PSNS activity, the main mechanism of action involving antagonism of muscarinic receptors resulting in increased heart rate and conduction velocity and stimulate bronchodilation.[8][9]

Within the SNS system, adrenoreceptor agonists/sympathomimetics work at alpha and beta receptors to potentiate SNS activity to achieve higher cardiac output and fast bronchodilation.[16][18] Inversely, adrenoreceptor antagonists are also active at alpha and beta receptors in decreasing SNS neurotransmission to reduce heart rate, dampen high catecholamine states, and increase urinary smooth muscle relaxation.[24][22][23]

Administration

Most agents are available as IV, IM, SC, PO formulations.[29][30][31] Some agents can also be given topically as eye drops, specific to ophthalmologic surgery requiring extended pupillary dilation and the medical treatment of open-angle and closed-angle glaucoma.[32][33]

Adverse Effects

Due to the various effects of the ANS on cardiovascular, pulmonary, gastrointestinal, and genitourinary systems, the general theme of reactions to these medications involves effects on these organ systems. The various reactions to each of the categories of agents include[16][18][24][22][23]:

• Cholinomimetics/cholinesterase inhibitors – nausea, vomiting, diarrhea, urinary urgency, excessive salivation, sweating, cutaneous vasodilation, bronchial constriction

• Anticholinergics – tachycardia, urinary retention, xerostomia (dry mouth), constipation, increased intraocular pressure

• Adrenoreceptor agonists/sympathomimetics – tremor, tachycardia, hypertension, urinary retention, piloerection

• Adrenoreceptor antagonists – bradycardia, bronchospasm, hypotension

Contraindications

Based on the adverse reaction profiles of each category, several significant contraindications can be elucidated[34][35][31]:

• Cholinomimetics/Cholinesterase inhibitors – relative contraindications in asthma/COPD, bradycardia, volume-depleted/hypotension, cardiogenic shock, sepsis, reduced ejection fraction heart failure

• Anticholinergics – relative contraindications in glaucoma especially angle-closure, older men with benign prostatic hyperplasia, and peptic ulcer disease; atropine specifically not recommended for children, especially infants who are sensitive to its hyperthermic effects

• Adrenoreceptor agonists/Sympathomimetics – relative contraindications in patients with a previous/current history of tachycardia or hypokalemia, hypertension, urinary retention, gastroparesis; for clonidine specifically in elderly who are more prone to fall from orthostatic hypotension, and epinephrine in those with angle-closure glaucoma

• Adrenoreceptor antagonists – relative contraindications for alpha-blockers in orthostatic hypotension, tachycardia, myocardial ischemia; for beta-blockers asthma/COPD for the nonselective agents, bradycardia, hypotension

Toxicity

Toxic profiles of the four categories described are mostly involved in overdose, exhibiting the same effects that are augmented so that the benefits no longer outweigh the risks. The primary reversal strategy for these situations typically is to discontinue the offending agent and treat the resultant symptoms.[1] Several agents of each category have toxic effects which require more specific reversal methods as listed[7][36][37][38]:

• Cholinesterase inhibitors (neostigmine, pyridostigmine, physostigmine) – formerly, high doses of these agents were used in chemical warfare would present as miosis, bronchial constriction, vomiting and diarrhea, and progress to convulsions, coma, and finally death; this toxicity profile remains the same and can be reversed with pralidoxime with adjunctive parenteral atropine and benzodiazepines for possible seizure activity

• Atropine – can cause vision disturbances when in excess resulting in prolonged mydriasis and cycloplegia, can also exacerbate closed-angle glaucoma by increasing intraocular pressure; reversal generally is to discontinue; however, physostigmine has utility in extreme cases such as severe elevation of body temperature and rapid supraventricular tachycardia

• Clonidine – can cause xerostomia and sedation; though currently there is no approved reversal, studies are currently investigating the use of naloxone as a reversal agent

• Beta-blockers – besides severe hypotension and bradycardia, tremors and bronchospasm are worrisome in the event of overdose; glucagon serves as the reversal agent

Enhancing Healthcare Team Outcomes

Healthcare professionals who prescribe medications that work on the autonomic system must be fully aware of the side effects of these agents. Requisite close monitoring of vital signs, including blood pressure, heart rate, respiratory rate, oxygen saturation, and the temperature is strongly recommended when attempting to reestablish autonomic homeostasis with ANS agents.[2] Several common conditions which require autonomic pharmacological correction need specific monitoring[39][40][41][42]:

• Glaucoma – ocular telemetry sensors can help to continuously monitor intraocular pressure.

• Shock – requires several monitoring functions as listed:

  • Maintaining a MAP of 65 and above

  • MAP measurements via an arterial line

  • Pulse pressure variation to guide fluid therapy

  • Bedside echocardiography to assess chambers of the heart and looking for cardiogenic shock vs. obstructive shock (massive PE) and calculate cardiac output/ejection fraction

  • Pulse index continuous cardiac output (PiCCO) device which can serve to continuously monitor continuous cardiac output and assess fluid response

• Asthma/COPD – pulmonary function testing is the standard to diagnose and monitor the severity of pulmonary obstruction; can also evaluate the effectiveness of inhaled autonomic agents in reversing obstructive processes

• Arrhythmias – for acute monitoring 4-lead ECG and 12-lead EKG are standard for monitoring tachycardias or bradycardias; if extended monitoring is required extended continuous ambulatory rhythm monitors (ECAM) is the monitoring modality of choice

Physicians, nurses, and pharmacists need to work collaboratively when using medications that interact with the autonomic nervous system to make sure that the pharmacotherapy is safe and effective for each patient. [Level V]

Review Questions

• Access free multiple choice questions on this topic.

• Comment on this article.

References

1.

Ibrahim MS, Samuel B, Mohamed W, Suchdev K. Cardiac Dysfunction in Neurocritical Care: An Autonomic Perspective. Neurocrit Care. 2019 Jun;30(3):508-521. [PubMed: 30484009]

2.

La Rovere MT, Christensen JH. The autonomic nervous system and cardiovascular disease: role of n-3 PUFAs. Vascul Pharmacol. 2015 Aug;71:1-10. [PubMed: 25869497]

3.

Patel HC, Rosen SD, Lindsay A, Hayward C, Lyon AR, di Mario C. Targeting the autonomic nervous system: measuring autonomic function and novel devices for heart failure management. Int J Cardiol. 2013 Dec 10;170(2):107-17. [PubMed: 24200312]

4.

Gaitonde S, Malik RD, Christie AL, Zimmern PE. Bethanechol: Is it still being prescribed for bladder dysfunction in women? Int J Clin Pract. 2019 Aug;73(8):e13248. [PubMed: 30112787]

5.

Mogil RS, Khezri N, Ren R, Adleyba O, Abumasmah R, Ghassibi MP, Chien JL, Pearlstein A, Patthanathamrongkasem T, Liebmann JM, Ritch R, Park SC. Changes in Iridocorneal Angle and Anterior Chamber Structure in Eyes With Anatomically Narrow Angles: Laser Iridotomy Versus Pilocarpine. J Glaucoma. 2018 Dec;27(12):1073-1078. [PubMed: 30256278]

6.

Watkins SL, Thrul J, Max W, Ling PM. Cold Turkey and Hot Vapes? A National Study of Young Adult Cigarette Cessation Strategies. Nicotine Tob Res. 2020 Apr 21;22(5):638-646. [PMC free article: PMC7171265] [PubMed: 30590749]

7.

Kumar A, Mehta V, Raj U, Varadwaj PK, Udayabanu M, Yennamalli RM, Singh TR. Computational and In-Vitro Validation of Natural Molecules as Potential Acetylcholinesterase Inhibitors and Neuroprotective Agents. Curr Alzheimer Res. 2019;16(2):116-127. [PubMed: 30543170]

8.

Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, Goldschlager NF, Hamilton RM, Joglar JA, Kim RJ, Lee R, Marine JE, McLeod CJ, Oken KR, Patton KK, Pellegrini CN, Selzman KA, Thompson A, Varosy PD. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2019 Aug 20;140(8):e382-e482. [PubMed: 30586772]

9.

Aziz MIA, Tan LE, Wu DB, Pearce F, Chua GSW, Lin L, Tan PT, Ng K. Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:3203-3231. [PMC free article: PMC6186767] [PubMed: 30349228]

10.

Dohar JE. Sialorrhea & aspiration control - A minimally invasive strategy uncomplicated by anticholinergic drug tolerance or tachyphylaxis. Int J Pediatr Otorhinolaryngol. 2019 Jan;116:97-101. [PubMed: 30554718]

11.

Herbison P, McKenzie JE. Which anticholinergic is best for people with overactive bladders? A network meta-analysis. Neurourol Urodyn. 2019 Feb;38(2):525-534. [PubMed: 30575999]

12.

Alammar N, Stein E. Irritable Bowel Syndrome: What Treatments Really Work. Med Clin North Am. 2019 Jan;103(1):137-152. [PubMed: 30466670]

13.

Bulka CM, Terekhov MA, Martin BJ, Dmochowski RR, Hayes RM, Ehrenfeld JM. Nondepolarizing Neuromuscular Blocking Agents, Reversal, and Risk of Postoperative Pneumonia. Anesthesiology. 2016 Oct;125(4):647-55. [PubMed: 27496656]

14.

Ohar J, Tosiello R, Goodin T, Sanjar S. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4. Int J Chron Obstruct Pulmon Dis. 2019;14:27-37. [PMC free article: PMC6305132] [PubMed: 30587959]

15.

Schuster Bruce C, Rull G, Sotiris A, Lobo MD. Novel stratified medicines approach to manage uncontrolled hypertension due to multiple drug intolerances. BMJ Case Rep. 2018 Dec 13;11(1) [PMC free article: PMC6301532] [PubMed: 30567232]

16.

Kislitsina ON, Rich JD, Wilcox JE, Pham DT, Churyla A, Vorovich EB, Ghafourian K, Yancy CW. Shock - Classification and Pathophysiological Principles of Therapeutics. Curr Cardiol Rev. 2019;15(2):102-113. [PMC free article: PMC6520577] [PubMed: 30543176]

17.

Beavers CJ, Pandya KA. Pharmacotherapy Considerations for the Management of Advanced Cardiac Life Support. Nurs Clin North Am. 2016 Mar;51(1):69-82. [PubMed: 26897425]

18.

Gardiner MA, Wilkinson MH. Randomized Clinical Trial Comparing Breath-Enhanced to Conventional Nebulizers in the Treatment of Children with Acute Asthma. J Pediatr. 2019 Jan;204:245-249.e2. [PubMed: 30392872]

19.

Szymanski MW, Richards JR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 8, 2023. Fenoldopam. [PubMed: 30252314]

20.

Sahney A, Sharma BC, Jindal A, Anand L, Arora V, Vijayaraghavan R, Dhamija RM, Kumar G, Bhardwaj A, Sarin SK. A double-blind randomized controlled trial to assess efficacy of bromocriptine in cirrhotic patients with hepatic parkinsonism. Liver Int. 2019 Apr;39(4):684-693. [PubMed: 30554466]

21.

Wu YP, Wang YB, Wu ZB. Bromocriptine-responsive supersellar germinoma with the expression of dopamine receptors: A case report. Clin Neurol Neurosurg. 2019 Jan;176:15-18. [PubMed: 30476699]

22.

Falhammar H, Kjellman M, Calissendorff J. Treatment and outcomes in pheochromocytomas and paragangliomas: a study of 110 cases from a single center. Endocrine. 2018 Dec;62(3):566-575. [PMC free article: PMC6244895] [PubMed: 30220006]

23.

Zabkowski T, Saracyn M. Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia. J Physiol Pharmacol. 2018 Aug;69(4) [PubMed: 30552307]

24.

Parch J, Powell C. No longer failing to treat heart failure: A guideline update review. JAAPA. 2019 Jan;32(1):11-15. [PubMed: 30589728]

25.

Philipp M, Brede M, Hein L. Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol. 2002 Aug;283(2):R287-95. [PubMed: 12121839]

26.

do Vale GT, Ceron CS, Gonzaga NA, Simplicio JA, Padovan JC. Three Generations of β-blockers: History, Class Differences and Clinical Applicability. Curr Hypertens Rev. 2019;15(1):22-31. [PubMed: 30227820]

27.

Bradley SJ, Tobin AB, Prihandoko R. The use of chemogenetic approaches to study the physiological roles of muscarinic acetylcholine receptors in the central nervous system. Neuropharmacology. 2018 Jul 01;136(Pt C):421-426. [PubMed: 29191752]

28.

Beaulieu JM, Espinoza S, Gainetdinov RR. Dopamine receptors - IUPHAR Review 13. Br J Pharmacol. 2015 Jan;172(1):1-23. [PMC free article: PMC4280963] [PubMed: 25671228]

29.

Carlson AB, Kraus GP. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 14, 2023. Physiology, Cholinergic Receptors. [PMC free article: PMC526134] [PubMed: 30252390]

30.

Broderick ED, Metheny H, Crosby B. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 30, 2023. Anticholinergic Toxicity. [PMC free article: PMC534798] [PubMed: 30521219]

31.

Farzam K, Kidron A, Lakhkar AD. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 2, 2023. Adrenergic Drugs. [PMC free article: PMC534230] [PubMed: 30480963]

32.

Moustafa GA, Borkar DS, McKay KM, Eton EA, Koulisis N, Lorch AC, Kloek CE., PCIOL Study Group. Outcomes in resident-performed cataract surgeries with iris challenges: Results from the Perioperative Care for Intraocular Lens study. J Cataract Refract Surg. 2018 Dec;44(12):1469-1477. [PubMed: 30391157]

33.

Adams CM, Stacy R, Rangaswamy N, Bigelow C, Grosskreutz CL, Prasanna G. Glaucoma - Next Generation Therapeutics: Impossible to Possible. Pharm Res. 2018 Dec 13;36(2):25. [PubMed: 30547244]

34.

Pecikoza U, Micov A, Tomić M, Stepanović-Petrović R. Eslicarbazepine acetate reduces trigeminal nociception: Possible role of adrenergic, cholinergic and opioid receptors. Life Sci. 2018 Dec 01;214:167-175. [PubMed: 30393024]

35.

Araklitis G, Thiagamoorthy G, Hunter J, Rantell A, Robinson D, Cardozo L. Anticholinergic prescription: are healthcare professionals the real burden? Int Urogynecol J. 2017 Aug;28(8):1249-1256. [PubMed: 28091711]

36.

Cole JB, Orozco BS, Arens AM. Physostigmine Reversal of Dysarthria and Delirium After Iatrogenic Atropine Overdose From a Dental Procedure. J Emerg Med. 2018 Jun;54(6):e113-e115. [PubMed: 29681419]

37.

Seger DL, Loden JK. Naloxone reversal of clonidine toxicity: dose, dose, dose. Clin Toxicol (Phila). 2018 Oct;56(10):873-879. [PubMed: 29544366]

38.

Lafarge L, Bourguignon L, Bernard N, Vial T, Dehan-Moya MJ, De La Gastine B, Goutelle S. [Pharmaco*kinetic risk factors of beta-blockers overdose in the elderly: Case report and pharmacology approach]. Ann Cardiol Angeiol (Paris). 2018 Apr;67(2):91-97. [PubMed: 29544975]

39.

Bozkurt B, Okudan N, Belviranli M, Oflaz AB. The evaluation of intraocular pressure fluctuation in glaucoma subjects during submaximal exercise using an ocular telemetry sensor. Indian J Ophthalmol. 2019 Jan;67(1):89-94. [PMC free article: PMC6324145] [PubMed: 30574900]

40.

Simmons J, Ventetuolo CE. Cardiopulmonary monitoring of shock. Curr Opin Crit Care. 2017 Jun;23(3):223-231. [PMC free article: PMC5678958] [PubMed: 28398907]

41.

Bokov P, Delclaux C. [Interpretation and use of routine pulmonary function tests: Spirometry, static lung volumes, lung diffusion, arterial blood gas, methacholine challenge test and 6-minute walk test]. Rev Med Interne. 2016 Feb;37(2):100-10. [PubMed: 26657268]

42.

Schultz KE, Lui GK, McElhinney DB, Long J, Balasubramanian V, Sakarovitch C, Fernandes SM, Dubin AM, Rogers IS, Romfh AW, Motonaga KS, Viswanathan MN, Ceresnak SR. Extended cardiac ambulatory rhythm monitoring in adults with congenital heart disease: Arrhythmia detection and impact of extended monitoring. Congenit Heart Dis. 2019 May;14(3):410-418. [PubMed: 30604934]

Disclosure: Derek Clar declares no relevant financial relationships with ineligible companies.

Disclosure: Sandeep Sharma declares no relevant financial relationships with ineligible companies.